Sickle Cell Anemia is a serious, genetic condition influencing the blood and different organs in the body. It influences the red platelets, causing scenes of sickling, which produce scenes of pain and different side effects. In the middle of scenes of sickling, individuals with sickle cell anemia are ordinarily well. Longstanding complications can happen. Certain conditions can trigger sickling, for example, cold, infection, absence of fluid in the body (dehydration) or low oxygen. Great treatment, began from the get-go throughout everyday life, can avert inconvenience. In this way, early analysis and authority treatment are prompted for advised for sickle cell anemia.
The Global Sickle Cell Anemia Therapeutics Market was valued at $ 2.26 bn in 2018 and is forecasted to grow at a significant 14.05% CAGR between 2018 and 2026, resulting in 2026 global sales of $ 6.46 bn. Market-driven by owing rising awareness regarding the disease and development in healthcare services. However, the staggering expense of treatment is restraining the market growth. Moreover, promising governmental initiatives are providing ample growth for the market.
Sickle Cell Anemia depending on treatment, hydroxyurea segment is expected to account for the largest share of the Sickle Cell Anemia market due to increasing the level of hemoglobin in the body. And, if taken regularly, it may help to reduce the number of symptoms such as pain episodes and acute chest syndrome. It recommended for the patients having moderate to severe pain episodes in a 12-month period, a history of stroke and a contraindication to chronic transfusions and a history of acute chest syndrome or symptomatic anemia.
The Global Sickle Cell Anemia Therapeutics Market is segmented on the basis of Treatment Type, End-User, and Region
Based on the Treatment Type: Pain Management, Prophylactic Therapy, Blood Transfusions, Hydroxyurea, Bone Marrow Transplantation.
Based on the End User: Private Clinics, Hospitals, and Other End Users
Based on the Region: North America, Asia-Pacific, Europe, and LAMEA. Among that North America held the largest share of the market owing to growing research and development activities, availability of better healthcare infrastructure and better reimbursement policies in the region which helps in maintaining a larger market share. Moreover, US country had a substantial lead in the number of sickle cell anemia clinical trials globally
The key players of the Global Sickle Cell Anemia Therapeutics Market include Bristol-Myers Squibb, Novartis, Pfizer, Emmaus Life Sciences, Bluebird Bio, Global Blood Therapeutics, Acceleron Pharma, Errant Gene Therapeutics, Gamida Cell, Modus Therapeutics, CSL Behring, Prolong Pharmaceuticals, Aruvant Sciences Inc, Forma Therapeutics Inc, Merck Sharp & Dohme Corp and CRISPR Therapeutics.
Report Description: The report covers in-depth analysis of the Global Sickle Cell Anemia Therapeutics Market. The report assesses the market products pipeline by Treatment (Pain Management, Prophylactic Therapy, Blood Transfusions, Hydroxyurea, Bone Marrow Transplantation) by end-user (Private Clinics, Hospitals, and Others). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations
The report includes in-depth company profiles of key players in the Global Sickle Cell Anemia Therapeutics Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.